© 1993 by Oxford University Press
Journal of the National Cancer Institute, Vol. 85, No. 20, 1657-1669,
October 20, 1993
© 1993 Oxford University Press
p53 Protein Accumulation and Gene Mutation in the Progression of Human Prostate Carcinoma
Science Park-Research Division, The University of Texas M. D. Anderson Cancer Center Smithville
Department of Pathology, The Unversity of Texas M. D. Anderson Cancer Center Houston
Department of Urology, The Unversity of Texas M. D. Anderson Cancer Center Houston
Department of Biomathematics, The University of Texas M. D. Anderson Cancer Center Houston
Department of Pathology, Fox Chase Cancer Center Philadelphia, Pa
Merck and Co. Research Laboratories West Point, Pa
Correspondence to:The University of Texas M. D. Anderson Cancer Center, Science Park-Research Division, P.O. Box 389, Smithville, TX 78957.
Background: Nuclear accumulation of p53 protein has been shown to be strongly associated with missense p53 mutations. Studies of nuclear accumulation of p53 protein in prostate carcinoma cells have to data been confined to material from primary tumors. Purpose: We studied the accumulation of p53 protein in specimens obtained from primary and metastatic sites of prostate carcinoma. By examining the accumulation of this protein as a function of stage, histologic grade, and androgen responsiveness of the tumor, we hoped to determine the role of p53 mutation in the progression of prostate carcinoma. Methods: The accumulation of the p53 protein in the cell nuclei was determined by immunohistochemical methods using polyclonal antibody to human p53 CM-1. The material studied consisted of formalin-fixed, paraffin-embedded tissue obtained from primary tumors and metastases of 92 patients with prostate carcinoma. Twelve samples from 11 patients were analyzed for the presence of mutations within exons 5–8 of the p53 gene (also known as TP53) by polymerase chain reaction-single-stranded conformation polymorphism (PCR-SSCP) analysis. Sequence analysis was subsequently performed on DNA obtained by polymerase chain reaction amplification of PCR-SSCP reactions produced from six different specimens. The chi-square test, Fisher's exact test, and the Freeman Halton test were used for statistical analyses of the results. Results: All tumors with p53 accumulation were metastatic (stage D), poorly differentiated, and androgen independent. Nuclear accumulation of p53 protein was strongly associated with stage (D2 versus D1 versus A-C, P<.0001), grade (Gleason score 8–10 versus 5–7, P<.003), and androgen sensitivity (androgen independent versus dependent, P<.0001). Logistic regression analysis demonstrated that androgen sensitivity predicted p53 outcome better than did stage (P<.0001) or grade alone (P<.006).
There was a perfect concordance between the results obtained by PCR-SSCP analysis and the p53 protein accumulation determined by immunohistochemistry in the 12 samples studied. Mutation of the p53 gene was confirmed by sequencing DNA obtained from six specimens positive in the PCR-SSCP assay. Conclusions: p53 gene mutation is a late event in the progression of prostate cancer and is associated with advanced (meta-static) stage, loss of differentiation, and the transition from androgen-dependent to androgen-independent growth. Implication: Testing of prostate cancer biopsy specimens from metastatic sites for p53 protein accumulation and gene mutation may provide useful prognostic information and could influence the recommended course of treatment. [J Natl Cancer Inst 85: 1657–1669, 1993]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T M Murphy, A S Perry, and M Lawler The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer Endocr. Relat. Cancer, March 1, 2008; 15(1): 11 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakahara, M. Takeuchi, I. Kinoyama, T. Minematsu, K. Shirasuna, A. Matsuhisa, A. Kita, F. Tominaga, K. Yamanaka, M. Kudoh, et al. YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts Cancer Res., September 1, 2007; 67(17): 8014 - 8021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Nagle, C. J. Bain, and P. M. Webb Cigarette Smoking and Survival after Ovarian Cancer Diagnosis Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2557 - 2560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pajonk, A. van Ophoven, and W. H. McBride Hyperthermia-Induced Proteasome Inhibition and Loss of Androgen Receptor Expression in Human Prostate Cancer Cells Cancer Res., June 1, 2005; 65(11): 4836 - 4843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Grizzle, D. G. Bostwick, H. Burke, O. W. Tawfik, D. McGregor, J. Cohn, and R. Lieberman Biomarkers in Prostate Cancer Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 196 - 204. [Full Text] [PDF]
|
|
|
|
|
|
S.-P. Huang, W.-J. Wu, W.-S. W. Chang, M.-T. Wu, Y.-Y. Chen, Y.-J. Chen, C.-C. Yu, T. T. Wu, Y.-H. Lee, J.-K. Huang, et al. p53 Codon 72 and p21 Codon 31 Polymorphisms in Prostate Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2217 - 2224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. SENGUPTA and B. WASYLYK Physiological and Pathological Consequences of the Interactions of the p53 Tumor Suppressor with the Glucocorticoid, Androgen, and Estrogen Receptors Ann. N.Y. Acad. Sci., June 1, 2004; 1024(1): 54 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Pisters, C. A. Pettaway, P. Troncoso, T. J. McDonnell, L. C. Stephens, C. G. Wood, K.-A. Do, S. M. Brisbay, X. Wang, E. A. Hossan, et al. Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer Clin. Cancer Res., April 15, 2004; 10(8): 2587 - 2593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Hernandez, L. A. Maddison, Y. Wei, F. DeMayo, T. Petras, B. Li, J. R. Gingrich, J. M. Rosen, and N. M. Greenberg Prostate-Specific Expression of p53R172L Differentially Regulates p21, Bax, and mdm2 to Inhibit Prostate Cancer Progression and Prolong Survival Mol. Cancer Res., December 1, 2003; 1(14): 1036 - 1047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.A. Schulz, M. Burchardt, and M.V. Cronauer Molecular biology of prostate cancer Mol. Hum. Reprod., August 1, 2003; 9(8): 437 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fizazi, J. Yang, S. Peleg, C. R. Sikes, E. L. Kreimann, D. Daliani, M. Olive, K. A. Raymond, T. J. Janus, C. J. Logothetis, et al. Prostate Cancer Cells-Osteoblast Interaction Shifts Expression of Growth/Survival-related Genes in Prostate Cancer and Reduces Expression of Osteoprotegerin in Osteoblasts Clin. Cancer Res., July 1, 2003; 9(7): 2587 - 2597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Nesslinger, X.-B. Shi, and R. W. deVere White Androgen-independent Growth of LNCaP Prostate Cancer Cells Is Mediated by Gain-of-Function Mutant p53 Cancer Res., May 1, 2003; 63(9): 2228 - 2233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Polek, L. V. Stewart, E. J. Ryu, M. B. Cohen, E. A. Allegretto, and N. L. Weigel p53 Is Required for 1,25-Dihydroxyvitamin D3-Induced G0 Arrest But Is Not Required for G1 Accumulation or Apoptosis of LNCaP Prostate Cancer Cells Endocrinology, January 1, 2003; 144(1): 50 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Martinez, J. Yang, E. S. Vazquez, M. del Carmen Rodriguez-Vargas, M. Olive, J.-T. Hsieh, C. J. Logothetis, and N. M. Navone p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells Carcinogenesis, August 1, 2002; 23(8): 1289 - 1296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Kiviharju, P. S. Lecane, R. G. Sellers, and D. M. Peehl Antiproliferative and Proapoptotic Activities of Triptolide (PG490), a Natural Product Entering Clinical Trials, on Primary Cultures of Human Prostatic Epithelial Cells Clin. Cancer Res., August 1, 2002; 8(8): 2666 - 2674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Claudio, A. Zamparelli, F. U. Garcia, L. Claudio, G. Ammirati, A. Farina, A. Bovicelli, G. Russo, G. G. Giordano, D. E. McGinnis, et al. Expression of Cell-Cycle-regulated Proteins pRb2/p130, p107, p27kip1, p53, mdm-2, and Ki-67 (MIB-1) in Prostatic Gland Adenocarcinoma Clin. Cancer Res., June 1, 2002; 8(6): 1808 - 1815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ren, L. Li, A. A. Goltsov, T. L. Timme, S. A. Tahir, J. Wang, L. Garza, A. C. Chinault, and T. C. Thompson mRTVP-1, a Novel p53 Target Gene with Proapoptotic Activities Mol. Cell. Biol., May 15, 2002; 22(10): 3345 - 3357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vanzulli, A. Efeyan, F. Benavides, L. A. Helguero, G. Peters, J. Shen, C. J. Conti, C. Lanari, and A. Molinolo p21, p27 and p53 in estrogen and antiprogestin-induced tumor regression of experimental mouse mammary ductal carcinomas Carcinogenesis, May 1, 2002; 23(5): 749 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fizazi, L. A. Martinez, C. R. Sikes, D. A. Johnston, L. C. Stephens, T. J. McDonnell, C. J. Logothetis, J. Trapman, L. L. Pisters, N. G. Ordonez, et al. The Association of p21(WAF-1/CIP1) with Progression to Androgen-independent Prostate Cancer Clin. Cancer Res., March 1, 2002; 8(3): 775 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Mikata, H. Uemura, H. Ohuchi, S. Ohta, Y. Nagashima, and Y. Kubota Inhibition of Growth of Human Prostate Cancer Xenograft by Transfection of p53 Gene: Gene Transfer by Electroporation Mol. Cancer Ther., February 1, 2002; 1(4): 247 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Ficazzola, M. Fraiman, J. Gitlin, K. Woo, J. Melamed, M. A. Rubin, and P. D. Walden Antiproliferative B cell translocation gene 2 protein is down-regulated post-transcriptionally as an early event in prostate carcinogenesis Carcinogenesis, August 1, 2001; 22(8): 1271 - 1279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Abate-Shen and M. M. Shen Molecular genetics of prostate cancer Genes & Dev., October 1, 2000; 14(19): 2410 - 2434. [Full Text]
|
|
|
|
|
|
D. I. Quinn, S. M. Henshall, D. R. Head, D. Golovsky, J. D. Wilson, P. C. Brenner, J. J. Turner, W. Delprado, J. F. Finlayson, P. D. Stricker, et al. Prognostic Significance of p53 Nuclear Accumulation in Localized Prostate Cancer Treated with Radical Prostatectomy Cancer Res., March 1, 2000; 60(6): 1585 - 1594. [Abstract] [Full Text]
|
|
|
|
|
|
N. M. Navone, M. d. C. Rodriguez-Vargas, W. F. Benedict, P. Troncoso, T. J. McDonnell, J.-H. Zhou, R. Luthra, and C. J. Logothetis TabBO: A Model Reflecting Common Molecular Features of Androgen-independent Prostate Cancer Clin. Cancer Res., March 1, 2000; 6(3): 1190 - 1197. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Chan, M. J. Stampfer, J. Ma, E. B. Rimm, W. C. Willett, and E. L. Giovannucci Supplemental Vitamin E Intake and Prostate Cancer Risk in a Large Cohort of Men in the United States Cancer Epidemiol. Biomarkers Prev., October 1, 1999; 8(10): 893 - 899. [Abstract] [Full Text]
|
|
|
|
|
|
E. Giovannucci, E. B. Rimm, A. Ascherio, G. A. Colditz, D. Spiegelman, M. J. Stampfer, and W. C. Willett Smoking and Risk of Total and Fatal Prostate Cancer in United States Health Professionals1 Cancer Epidemiol. Biomarkers Prev., April 1, 1999; 8(4): 277 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken Molecular Genetics and Epidemiology of Prostate Carcinoma Endocr. Rev., February 1, 1999; 20(1): 22 - 45. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Srivastava, L. Bubendorf, V. Srikantan, L. Fossom, L. Nolan, M. Glasman, X. Leighton, W. Fehrle, S. Pittaluga, M. Raffeld, et al. ANX7, a candidate tumor suppressor gene for prostate cancer PNAS, April 10, 2001; 98(8): 4575 - 4580. [Abstract] [Full Text] [PDF]
|
|